CYP2C19 gene polymorphism may be a risk factor for bronchial asthma

Medical Principles and Practice

Volumn 20, Issue 1, 2010, Pages 39-42

  Yaroǧlu, Hatice Yildirim ^a   Çalikoǧlu, Mukadder ^a   Gümüş, Lülüfer Tamer ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Asthma; CYP2C19; Gene polymorphism

Indexed keywords

CYTOCHROME P450 2C19;

ADULT; ALLELE; ANALYTICAL EQUIPMENT; ARTICLE; ASTHMA; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; WILD TYPE;

ADULT; AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASTHMA; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS; TURKEY; YOUNG ADULT;

EID: 78650469282     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322077     Document Type: Article

References (21)

1. National Asthma Education Program 1995: Role of the pharmacist in improving asthma care. Am J Health Syst Pharm 1995;52:1411-1416.
2. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM: Economic burden of asthma: a systematic review. BMC Pulm Med 2009;9:24.
3. Ivaschenko TE, Sideleva OG, Baranov V: Glutathione-S-transferase micro and theta gene polymorphisms as new risk factors of atopic bronchial asthma. J Mol Med 2002;80:39-43.
4. Pons F, Haag M, Corcos L, Bonnet P, Guillouzo A, Lugnier A, Frossard N: Inhalation of toluene diisocyanate affects cytochrome P450 2B1 expression in rat lung. Arch Toxicol 2000;74:397-403.
5. Goldstein JA, de Morais S M F: Biochemistry and molecular biology of human CYP2C subfamily. Pharmacogenetics 1994;4:285-299.
6. Nelson DR, Koymans L, Kamataki Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
7. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-15422.
8. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-598.
9. American Thoracic Society: Standards for diagnosis of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-244.
10. Niewinski P, Orzechowska-Juzwenko K, Patkowski J, Medrala W, Wolanczyk-Medrala A, Hurkacz M: Significance of CYP2D6 oxidation genotype as a risk factor in development of allergic diseases. Pol Arch Med Wewn 2003;109:137-142.
11. Tamer L, Calikoglu M, Ates NA, Yildirim H, Ercan B, Saritas E, Unlü A, Atik U: Glutathione-S-transferase gene polymorphisms (GSTT1, GSTM1, GSTP1) as increased risk factors for asthma. Respirology 2004;9:493-498.
12. Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A, Pelkonen O: Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - a review. Gene 1995;159:113-121.
13. Zielinska E, Niewiarowski W, Bodalski J, Stañczyk A, Bolanowski W, Rebowski G: Arylamine N-acetyltransferase NAT2 gene mutations in children with allergic diseases. Clin Pharmacol Ther 1997;626:635-642.
14. Vavilin VA, Makarova SI, Liakhovich VV, Gavalov SM: Polymorphic genes of xenobioticmetabolizing enzymes associated with bronchial asthma in genetically predisposed children. Genetika 2002;384:539-545.
15. Wikman H, Piirila P, Rosenberg C, Luukkonen R, Kääriä K, Nordman H, Norppa H, Vainio H, Hirvonen A: N-Acetyltransferase genotypes as modifiers of diisocyanate exposureassociated asthma risk. Pharmacogenetics 2002;123:227-233.
16. * genotype in children with bronchial asthma and other atopic diseases. Ann Acad Med Stetin 1999;45:109-121.
17. Gawronska-Szklarz B, Luszawska-Kutrzeba T, Czaja-Bulsa G, Kurzawski G: Relationship between acetylation polymorphism and risk of atopic diseases. Clin Pharmacol Ther 1999;655:562-569.
18. Zielinska E, Niewiarowski W, Bodalski J, Stanczyk A, Bolanowski W, Rebowski G: Arylamine N-acetyltransferase NAT2 gene mutations in children with allergic diseases. Clin Pharmacol Ther 1997;626:635-642.
19. Orzechowska-Juzwenko K, Milejski P, Patkowski J, Nittner-Marszalska M, Malolepszy J: Acetylator phenotype in patients with allergic diseases and its clinical significance. Int J Clin Pharmacol Ther Toxicol 1990;28:420-425.
20. Nacak M, Aynacioglu AS, Filiz A, Cascorbi I, Erdal ME, Yilmaz N, Ekinci E, Roots I: Association between the N-acetylation genetic polymorphism and bronchial asthma. Br J Clin Pharmacol 2002;546:671-674.
21. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, Kayaalp SO, Roots I, Brockmöller J: Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999;66:185-192.